Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know
Immune checkpoint inhibitors (ICI) represent a new revolutionary weapon in the armamentarium of anti-cancer therapies. The side effects of these new agents represent a new challenge for oncologists; they are usually unpredictable and sometimes life threatening, if not managed rapidly and adequately....
Gespeichert in:
| Veröffentlicht in: | Immunotherapy 2016-12, Vol.8 (12), p.1437-1446 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1446 |
|---|---|
| container_issue | 12 |
| container_start_page | 1437 |
| container_title | Immunotherapy |
| container_volume | 8 |
| creator | Habre, Maya Habre, Samer Bassilios Kourie, Hampig R |
| description | Immune checkpoint inhibitors (ICI) represent a new revolutionary weapon in the armamentarium of anti-cancer therapies. The side effects of these new agents represent a new challenge for oncologists; they are usually unpredictable and sometimes life threatening, if not managed rapidly and adequately. The most frequent side effects are the dermatologic, but they are usually low grade side effects and consequently easily manageable. Rash, pruritus and vitiligo are the most frequent dermatologic side effects. We aimed in this review to describe first all the dermatologic side effects of ICI according to the subtype of ICI and combination therapies in the clinical trials, then to report all the rare case reports dermatologic side effects, and finally to present the management algorithm of these side effects. |
| doi_str_mv | 10.2217/imt-2016-0074 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859471901</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1859471901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-f99b435a9cf60a8a3ec7728b338118e8cdef8101685c24dad7f34d22f963bcd93</originalsourceid><addsrcrecordid>eNp1kDtPHTEQRq0oKDySMi2ylCbNgl-79qZDhEckJBqQ0lle7zjXsGvf2F4Q_x7fXKBASjUz0plPMwehr5QcMUblsZ9LwwjtGkKk-ID2qGxJI4VQH996_nsX7ed8R0gnZCc-oV2mCCEtb_fQzU9Isylxin-8xWZ8gJQBwwOEknF02K7A3q-jDwX7sPKDLzHlH_hxZQo2Acdg_63mgvMqLtOI70N8_Ix2nJkyfHmpB-j2_Ozm9LK5ur74dXpy1VhBRGlc3w-Ct6a3riNGGQ5WSqYGzhWlCpQdwSlaf1OtZWI0o3RcjIy5vuODHXt-gL5vc9cp_l0gFz37bGGaTIC4ZE1V2wtJe0Ir-u0deheXFOp1mnHG6xmsE5VqtpRNMecETq-Tn0160pTojW5ddeuNbr3RXfnDl9RlmGF8o1_9VqDfAm4pS4JsPQQLejvVDW99gP-EPwP7Io8T</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2323435264</pqid></control><display><type>article</type><title>Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know</title><source>MEDLINE</source><source>PubMed Central</source><creator>Habre, Maya ; Habre, Samer Bassilios ; Kourie, Hampig R</creator><creatorcontrib>Habre, Maya ; Habre, Samer Bassilios ; Kourie, Hampig R</creatorcontrib><description>Immune checkpoint inhibitors (ICI) represent a new revolutionary weapon in the armamentarium of anti-cancer therapies. The side effects of these new agents represent a new challenge for oncologists; they are usually unpredictable and sometimes life threatening, if not managed rapidly and adequately. The most frequent side effects are the dermatologic, but they are usually low grade side effects and consequently easily manageable. Rash, pruritus and vitiligo are the most frequent dermatologic side effects. We aimed in this review to describe first all the dermatologic side effects of ICI according to the subtype of ICI and combination therapies in the clinical trials, then to report all the rare case reports dermatologic side effects, and finally to present the management algorithm of these side effects.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2016-0074</identifier><identifier>PMID: 28000535</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Algorithms ; Animals ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; autoimmunity ; cancer immunology ; Cancer therapies ; Case reports ; checkpoint inhibitors ; Clinical trials ; Clinical Trials as Topic ; Costimulatory and Inhibitory T-Cell Receptors - antagonists & inhibitors ; Diarrhea ; Disease Management ; Drug-Related Side Effects and Adverse Reactions - therapy ; Exanthema - etiology ; Exanthema - therapy ; Humans ; Hypothyroidism ; Immune checkpoint inhibitors ; immune-related adverse events ; Immunotherapy ; Immunotherapy - adverse effects ; Immunotherapy - methods ; Inflammatory bowel disease ; Melanoma ; Metastasis ; Neoplasms - complications ; Neoplasms - immunology ; Neoplasms - therapy ; Pruritus ; Pruritus - etiology ; Pruritus - therapy ; Response rates ; Side effects ; Skin ; skin manifestations ; Vitiligo ; Vitiligo - etiology ; Vitiligo - therapy</subject><ispartof>Immunotherapy, 2016-12, Vol.8 (12), p.1437-1446</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Dec 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-f99b435a9cf60a8a3ec7728b338118e8cdef8101685c24dad7f34d22f963bcd93</citedby><cites>FETCH-LOGICAL-c404t-f99b435a9cf60a8a3ec7728b338118e8cdef8101685c24dad7f34d22f963bcd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28000535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Habre, Maya</creatorcontrib><creatorcontrib>Habre, Samer Bassilios</creatorcontrib><creatorcontrib>Kourie, Hampig R</creatorcontrib><title>Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know</title><title>Immunotherapy</title><addtitle>Immunotherapy</addtitle><description>Immune checkpoint inhibitors (ICI) represent a new revolutionary weapon in the armamentarium of anti-cancer therapies. The side effects of these new agents represent a new challenge for oncologists; they are usually unpredictable and sometimes life threatening, if not managed rapidly and adequately. The most frequent side effects are the dermatologic, but they are usually low grade side effects and consequently easily manageable. Rash, pruritus and vitiligo are the most frequent dermatologic side effects. We aimed in this review to describe first all the dermatologic side effects of ICI according to the subtype of ICI and combination therapies in the clinical trials, then to report all the rare case reports dermatologic side effects, and finally to present the management algorithm of these side effects.</description><subject>Algorithms</subject><subject>Animals</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>autoimmunity</subject><subject>cancer immunology</subject><subject>Cancer therapies</subject><subject>Case reports</subject><subject>checkpoint inhibitors</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Costimulatory and Inhibitory T-Cell Receptors - antagonists & inhibitors</subject><subject>Diarrhea</subject><subject>Disease Management</subject><subject>Drug-Related Side Effects and Adverse Reactions - therapy</subject><subject>Exanthema - etiology</subject><subject>Exanthema - therapy</subject><subject>Humans</subject><subject>Hypothyroidism</subject><subject>Immune checkpoint inhibitors</subject><subject>immune-related adverse events</subject><subject>Immunotherapy</subject><subject>Immunotherapy - adverse effects</subject><subject>Immunotherapy - methods</subject><subject>Inflammatory bowel disease</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Pruritus</subject><subject>Pruritus - etiology</subject><subject>Pruritus - therapy</subject><subject>Response rates</subject><subject>Side effects</subject><subject>Skin</subject><subject>skin manifestations</subject><subject>Vitiligo</subject><subject>Vitiligo - etiology</subject><subject>Vitiligo - therapy</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kDtPHTEQRq0oKDySMi2ylCbNgl-79qZDhEckJBqQ0lle7zjXsGvf2F4Q_x7fXKBASjUz0plPMwehr5QcMUblsZ9LwwjtGkKk-ID2qGxJI4VQH996_nsX7ed8R0gnZCc-oV2mCCEtb_fQzU9Isylxin-8xWZ8gJQBwwOEknF02K7A3q-jDwX7sPKDLzHlH_hxZQo2Acdg_63mgvMqLtOI70N8_Ix2nJkyfHmpB-j2_Ozm9LK5ur74dXpy1VhBRGlc3w-Ct6a3riNGGQ5WSqYGzhWlCpQdwSlaf1OtZWI0o3RcjIy5vuODHXt-gL5vc9cp_l0gFz37bGGaTIC4ZE1V2wtJe0Ir-u0deheXFOp1mnHG6xmsE5VqtpRNMecETq-Tn0160pTojW5ddeuNbr3RXfnDl9RlmGF8o1_9VqDfAm4pS4JsPQQLejvVDW99gP-EPwP7Io8T</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Habre, Maya</creator><creator>Habre, Samer Bassilios</creator><creator>Kourie, Hampig R</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20161201</creationdate><title>Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know</title><author>Habre, Maya ; Habre, Samer Bassilios ; Kourie, Hampig R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-f99b435a9cf60a8a3ec7728b338118e8cdef8101685c24dad7f34d22f963bcd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Algorithms</topic><topic>Animals</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>autoimmunity</topic><topic>cancer immunology</topic><topic>Cancer therapies</topic><topic>Case reports</topic><topic>checkpoint inhibitors</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Costimulatory and Inhibitory T-Cell Receptors - antagonists & inhibitors</topic><topic>Diarrhea</topic><topic>Disease Management</topic><topic>Drug-Related Side Effects and Adverse Reactions - therapy</topic><topic>Exanthema - etiology</topic><topic>Exanthema - therapy</topic><topic>Humans</topic><topic>Hypothyroidism</topic><topic>Immune checkpoint inhibitors</topic><topic>immune-related adverse events</topic><topic>Immunotherapy</topic><topic>Immunotherapy - adverse effects</topic><topic>Immunotherapy - methods</topic><topic>Inflammatory bowel disease</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Pruritus</topic><topic>Pruritus - etiology</topic><topic>Pruritus - therapy</topic><topic>Response rates</topic><topic>Side effects</topic><topic>Skin</topic><topic>skin manifestations</topic><topic>Vitiligo</topic><topic>Vitiligo - etiology</topic><topic>Vitiligo - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Habre, Maya</creatorcontrib><creatorcontrib>Habre, Samer Bassilios</creatorcontrib><creatorcontrib>Kourie, Hampig R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Habre, Maya</au><au>Habre, Samer Bassilios</au><au>Kourie, Hampig R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know</atitle><jtitle>Immunotherapy</jtitle><addtitle>Immunotherapy</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>8</volume><issue>12</issue><spage>1437</spage><epage>1446</epage><pages>1437-1446</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>Immune checkpoint inhibitors (ICI) represent a new revolutionary weapon in the armamentarium of anti-cancer therapies. The side effects of these new agents represent a new challenge for oncologists; they are usually unpredictable and sometimes life threatening, if not managed rapidly and adequately. The most frequent side effects are the dermatologic, but they are usually low grade side effects and consequently easily manageable. Rash, pruritus and vitiligo are the most frequent dermatologic side effects. We aimed in this review to describe first all the dermatologic side effects of ICI according to the subtype of ICI and combination therapies in the clinical trials, then to report all the rare case reports dermatologic side effects, and finally to present the management algorithm of these side effects.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>28000535</pmid><doi>10.2217/imt-2016-0074</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-743X |
| ispartof | Immunotherapy, 2016-12, Vol.8 (12), p.1437-1446 |
| issn | 1750-743X 1750-7448 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1859471901 |
| source | MEDLINE; PubMed Central |
| subjects | Algorithms Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use autoimmunity cancer immunology Cancer therapies Case reports checkpoint inhibitors Clinical trials Clinical Trials as Topic Costimulatory and Inhibitory T-Cell Receptors - antagonists & inhibitors Diarrhea Disease Management Drug-Related Side Effects and Adverse Reactions - therapy Exanthema - etiology Exanthema - therapy Humans Hypothyroidism Immune checkpoint inhibitors immune-related adverse events Immunotherapy Immunotherapy - adverse effects Immunotherapy - methods Inflammatory bowel disease Melanoma Metastasis Neoplasms - complications Neoplasms - immunology Neoplasms - therapy Pruritus Pruritus - etiology Pruritus - therapy Response rates Side effects Skin skin manifestations Vitiligo Vitiligo - etiology Vitiligo - therapy |
| title | Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A36%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dermatologic%20adverse%20events%20of%20checkpoint%20inhibitors:%20what%20an%20oncologist%20should%20know&rft.jtitle=Immunotherapy&rft.au=Habre,%20Maya&rft.date=2016-12-01&rft.volume=8&rft.issue=12&rft.spage=1437&rft.epage=1446&rft.pages=1437-1446&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2016-0074&rft_dat=%3Cproquest_cross%3E1859471901%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2323435264&rft_id=info:pmid/28000535&rfr_iscdi=true |